Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 168   

Articles published

NVS 81.29 +0.87 (1.08%)
price chart
Here's Why You Should Buy Novartis AG (ADR) (NYSE:NVS)
Although Swiss pharmaceutical company Novartis AG (ADR) (NYSE:NVS) missed analysts' expectations on its fourth quarter report, the company is in a strong position due to its diversified business model and product pipeline.
Novartis AG (ADR) (NVS) is Upgraded by Societe Generale to ” Buy”  Highland Mirror
Exane BNP Paribas Cuts Novartis AG (NVS) To “Underperform” from “Neutral ... ...  Wolcott Daily
Novartis AG (ADR) (NYSE:NVS) Denies It Is Selling Its Portfolio of Respiratory ...
Novartis AG (ADR) (NYSE:NVS) has denied reports that it intends to sell off some of its drugs that are used in the treatment of COPD and asthma.
GlaxoSmithKline Plc (ADR) (NYSE:GSK) Considering Acquiring Novartis AG (ADR ...
Reports indicate that GlaxoSmithKline plc (ADR) (NYSE:GSK) is considering plans to acquire a stake that is held by Novartis AG (ADR) (NYSE:NVS) in their consumer healthcare joint venture. Currently, Novartis owns 36.5% of GSK Consumer Healthcare, ...
Bullish Pharma stock today: Novartis AG (ADR)(NYSE: NVS)
Novartis AG (ADR)(NYSE: NVS) will look for medicines that are in earlier stages of development as acquisition price tags climb across the industry.
Novartis AG (ADR) (NVS) Releases Earnings Results, Beats Expectations By $0 ...  Highland Mirror
Novartis AG (ADR) (NYSE:NVS) Shares Rise Despite Mixed Results  Stock Market Daily
Golar LNG Partners LP (GMLP) EPS Estimated At $0.44; Novartis AG (ADR) (NVS ...
Analysts expect Golar LNG Partners LP (NASDAQ:GMLP) to report $0.44 EPS on May, 30.They anticipate $0.07 EPS change or 18.92% from last quarter's $0.37 EPS.
Novartis AG (ADR) (NYSE:NVS) Likely to Recover From Headwinds
Portfolio Manager Donald Woodley of Woodley Farra Manion Portfolio Management says that while Novartis AG (ADR) (NYSE:NVS) has had challenges in its eye care and generics divisions, it is a solid company that should recover from its out-of-favor status.
Novartis AG (ADR) (NYSE:NVS)'s push to win approval for Zykadia
Novartis AG (NYSE:NVS)'s push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
Stock's Buzzers Gulfport Energy Corporation (NASDAQ:GPOR), Novartis AG (ADR ...
Shares of Novartis AG (ADR) (NYSE:NVS) inclined 0.96% to $77.06. Stock exchanged hands with the total volume of 3.73.
Analyst's Report Recap: Novartis AG (ADR) (NYSE:NVS)
Novartis AG (ADR) (NYSE:NVS) plunged -1.16% during previous trade, a total of 2.28M shares exchanged hands compared with its average trading volume of 2.33M shares whereas its relative volume is 0.74.
KeyCorp (NYSE:KEY) & Novartis AG (ADR) (NYSE:NVS) Worth Watching Stocks  Stock Watch (press release)
Stocks under Discussion: Cobalt International Energy, Inc. (NYSE:CIE ...  Wall Street Times (press release)
Ionis Pharmaceuticals Inc (IONS), Akcea Strike Favorable Deal with Novartis AG ...
Ionis Pharmaceuticals Inc (NASDAQ:IONS) shares were initially up 6% this morning after the biotech firm and its wholly-owned subsidiary Akcea Therapeutics signed an exclusive cardiovascular disease treatment collaborative agreement with Novartis AG ...
Novartis in $1.6 bln deal for Ionis, Akcea drugs  MarketWatch